Rubicon OrganicsROMJF 50 Debt-to-Equity is 0.32 as of Mar. 2026, which is 19% above its 10-year median of 0.27. GuruFocus rates ROMJF with a GF Score™ of 50/100 and a GF Value™ of $0.37 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 810 Drug Manufacturers companies, Rubicon Organics ranks worse than 54.44% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Rubicon Organics's Debt-to-Equity or its related term are showing as below:
ROMJF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.27 Max: 0.94
Current: 0.32
During the past 10 years, the highest Debt-to-Equity Ratio of Rubicon Organics was 0.94. The lowest was 0.02. And the median was 0.27.
ROMJF's Debt-to-Equity is ranked worse than 54.44% of 810
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs ROMJF: 0.32
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Rubicon Organics Debt-to-Equity Related Terms
Rubicon Organics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Rubicon Organics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Rubicon Organics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rubicon Organics Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rubicon Organics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Rubicon Organics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rubicon Organics (ROMJF) has a Debt-to-Equity of 0.32 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Rubicon Organics and its competitors. This is 19% above median its historical median of 0.27. Over the past decade, Rubicon Organics' Debt-to-Equity has ranged from 0.02 to 0.94. According to the industry distribution chart, Rubicon Organics ranks #441 out of 810 companies in the Drug Manufacturers industry, placing it in the top 54.4%.
Is Rubicon Organics' Debt-to-Equity too high?
Rubicon Organics' current Debt-to-Equity of 0.32 is 19% above median its 10-year median of 0.27. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.94. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Rubicon Organics' value of 0.32 is 18.5% above this industry median. Based on the distribution chart, Rubicon Organics ranks #441 out of 810 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Rubicon Organics has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rubicon Organics' Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Rubicon Organics ranks #441 out of 810 companies for Debt-to-Equity. This places Rubicon Organics in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Rubicon Organics' value of 0.32 is 18.5% above this benchmark. Historically, Rubicon Organics' own Debt-to-Equity has ranged from 0.02 to 0.94 over the past decade. While the company's 10-year median is 0.27 vs. the industry median of 0.27, Rubicon Organics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rubicon Organics's current Debt-to-Equity of 0.32 is 18.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Rubicon Organics and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rubicon Organics's current Debt-to-Equity is 0.32, which is 19% above median its own 10-year median of 0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rubicon Organics stock overvalued right now?
Based on GuruFocus' analysis, Rubicon Organics (ROMJF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.37, compared to a current price of $0.32 — trading 13.2% below its estimated fair value. The current Debt-to-Equity is 0.32, which is 19% above median its 10-year median of 0.27 and 18.5% above the Drug Manufacturers industry median of 0.27. Rubicon Organics' overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Rubicon Organics (ROMJF), the current Debt-to-Equity is 0.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rubicon Organics (ROMJF) Overvalued in 2026?
Based on GuruFocus' analysis, Rubicon Organics stock appears to be undervalued.
The current stock price of $0.32 is trading 13.2% below its estimated GF Value™ of $0.37.
GuruFocus considers Rubicon Organics to be Modestly Undervalued.
Key valuation signals for ROMJF:
Debt-to-Equity: 0.32 (19% above median its 10-year median of 0.27)
GF Value™: $0.37 vs. price of $0.32 (13.2% below fair value)
Industry Position: 18.5% above the Drug Manufacturers median (#441 of 810)
No single metric tells the full story. See the ROMJF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rubicon Organics Inc is engaged in the production and sale of cannabis in Canada. The company produces and processes organic cannabis at its wholly owned, federally licensed 125,000 square foot facility in Delta, British Columbia which it sells under its wholly owned brands and certain wholesale channels. Its brands include Simply Bare, 1964 Supply Co, Wildflower, and Homestead Cannabis Supply. It operates in a single reportable segment, being the production and sale of cannabis in Canada.
50GF Score
Get the complete analysis for ROMJF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROMJF has been successfully added to your 
